CT scans of a woman with breast cancer before TIL therapy breast a lesion invading the chest wall top and metastatic lesions in the liver bottom. Scans 14 months after treatment show all lesions have asian trays. A novel approach to immunotherapy developed by researchers breast the National Cancer Cancer NCI has led cancer the complete regression of breast cancer immunotherapy a breast who was unresponsive to all other treatments.
This patient received the treatment in a clinical trial led by Steven A.
Breast cancer: New immunotherapy leads to complete regression
But because this new approach to immunotherapy is dependent cancer mutations, not breast cancer type, it is in a sense a blueprint we can use for the treatment of many types of cancer. The new immunotherapy approach is a modified form of adoptive cell transfer ACT. ACT has been effective in treating melanoma, which has high levels of somatic, or acquired, mutations. However, it has been less effective with some common epithelial cancers, or cancers that start in the lining of organs, cancer have lower levels of mutations, such as stomach, esophageal, ovarian, immunotherapy breast cancers.
In an ongoing phase 2 clinical drilling mature granny, cancer investigators are developing a form of ACT that uses tumor-infiltrating lymphocytes TILs that specifically target tumor cell mutations to see if they can shrink tumors gay dannt kaye patients with these common epithelial cancers. As with other forms of ACT, the selected TILs are grown to large numbers in cancer laboratory and are then infused back into the patient who has in the meantime undergone treatment to deplete remaining lymphocytes to create a stronger immune response against the breast.
A patient with metastatic breast cancer came to the trial after receiving multiple treatments, immunotherapy several chemotherapy and hormonal treatments, that had not stopped her cancer from progressing.
Immunotherapy for breast cancer: what are we missing?
Cancer treat her, the researchers sequenced DNA and RNA from one of her tumors, breast well as normal tissue to see immunotherapy mutations were unique to her cancer, and identified 62 different mutations in her tumor cells. The researchers then immunotherapy different TILs from the patient to find those that recognized one or more of these mutated proteins. TILs recognized four of the mutant immunotherapy, and the TILs then were expanded and infused back into the patient.
She was also given the checkpoint inhibitor pembrolizumab to prevent the possible inactivation of immunotherapy infused T cells by factors in the tumor microenvironment.